Relatives of patients with systemic lupus erythematosus - antinuclear antibodies, immunological profile and risk of developing the disease
Vol. 30 No. 2 (2022), Review articles
Vol. 30 No. 2 (2022)

Relatives of patients with systemic lupus erythematosus - antinuclear antibodies, immunological profile and risk of developing the disease

Review articles
https://doi.org/10.35465/30.2.2022.pp68-84
Published August 24, 2022
Bogdan Frediev Penev
Internal Medicine Department, St Anna Univeristy Hospital, Sofia
https://orcid.org/0000-0001-5005-4259
Georgi Vasilev
Dobroslav Kyurkchiev
Simeon Monov
PDF EN
PDF BG (Български)

How to Cite

Penev, B., Vasilev, G., Kyurkchiev, D., & Monov, S. (2022). Relatives of patients with systemic lupus erythematosus - antinuclear antibodies, immunological profile and risk of developing the disease. Rheumatology (Bulgaria), 30(2), 68-84. https://doi.org/10.35465/30.2.2022.pp68-84
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Резюме. Системният лупус еритематозус е системно автоимунно заболяване, което в действителност започва години преди клиничното начало с поява на антинуклеарни антитела и имунологични признаци на дисрегулация в серума. Същевременно, поради тенденцията към фамилна агрегация, рискът за развитието на болест у роднините на болните и няколко десетки пъти по-голям. При изследвания, у роднините на болните се намират антинуклеарни антитела значително по-често отколкото в общата популация, а комбинация от повишени проинфламаторни и намалени регулаторни цитокини може да бъде предиктивна по отношение на рисковите индивиди, които следва да се предпазват от въздействието на рискови фактори или дори да предприемат профилактично медикаменти. Настоящият литературен обзор предлага обобщение на съвременните литературни данни по темата.

https://doi.org/10.35465/30.2.2022.pp68-84
PDF EN
PDF BG (Български)

References

  1. References:
  2. Alba, P. (2003). Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Annals of the Rheumatic Diseases, 62(6), pp.556-560.
  3. Swaak, A., Huysen, V., Nossent, J. and Smeenk, R. (1990). Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clinical Rheumatology, 9(S1), pp.82-95.
  4. Alspaugh, M., Talal, N. and Tan, E. (1976). Differentiation and characterization of autoantibodies and their antigens in sjögren's syndrome. Arthritis & Rheumatism, 19(2), pp.216-222.
  5. Lim, S., Bayakly, A., Helmick, C., Gordon, C., Easley, K. and Drenkard, C. (2014). The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis & Rheumatology, 66(2), pp.357-368.
  6. Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 2014;66(2):369-378.
  7. Ferucci ED, Johnston JM, Gaddy JR, et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. Arthritis Rheumatol. 2014;66(9):2494-2502.
  8. Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013;65(3):753-763.
  9. Rees F1, Doherty M, Grainge MJ, Lanyon P, Zhang W, The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies, Rheumatology, 2017 Nov 1;56(11):1945-1961.
  10. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003;48(8):2100-2110.
  11. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251-1262.
  12. Bernier MO, Mikaeloff Y, Hudson M, et al. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 2009;61(4):476-481.
  13. Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette Smoking and the Risk of Systemic Lupus Erythematosus: A Meta-Analysis. Arthritis Rheum. 2004;50:849-857.
  14. Bae SC, Kim SJ, Sung MK. Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatol Int. 2002;22(6):238-243.
  15. Costenbader, K., Feskanich, D., Holmes, M., Karlson, E. and Benito-Garcia, E. (2007). Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Annals of the Rheumatic Diseases, 67(4), pp.530-535.
  16. Hiraki, L., Munger, K., Costenbader, K. and Karlson, E. (2012). Dietary intake of vitamin D during adolescence and risk of adult-onset systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care & Research, 64(12), pp.1829-1836.
  17. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100(12):3019-3026;
  18. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44(5):1122-1126.
  19. Ulff-Moller CJ, Nielsen NM, Rostgaard K, et al. Epstein-Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology (Oxford), 2010;49(9):1706-1712.
  20. Parks CG, Cooper GS, Nylander-French LA, et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum. 2002;46(7):1840-1850.
  21. Finckh A, Cooper GS, Chibnik LB, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 2006;54(11):3648-3654.
  22. Giles I, Isenberg D. Lupus in the family: analysis of a cohort followed from 1978 to 1999. Lupus 2001;10:38–44.
  23. Eroglu GE, Kohler PF. Familial systemic lupus erythematosus: the role of genetic and environmental factors. Ann Rheum Dis 2002;61:29–31.
  24. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus еrythematosus: allergies, infections, and family history. J Clin Epidemiol 2002;55:982–9.
  25. Sato EI, Atra E, Gabriel A Jr, Masi AT. Systemic lupus erythematosus: a family study of 25 probands. Clin Exp Rheumatol 1991;9:455–61.
  26. Alarcón-Segovia, D., Alarcón-Riquelme, M., Cardiel, M., Caeiro, F., Massardo, L., Villa, A. and Pons-Estel, B. (2005). Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis & Rheumatism, 52(4), pp.1138-1147.
  27. Bergsteindottir K и сътр., Evidence of common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models of multiple sclerosis and rheumatoid arthritis. J Immunol 2000;164:1564–8.
  28. D. Alarcón-Segovia, Eugenia Fishbein; Serum Immunoglobulins in Systemic Lupus Erythematosus. Clin Sci 1 July 1972; 43 (1): 121–131.
  29. Guerrier, T., Youinou, P., Pers, J. O. & Jamin, C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J. Autoimmun. 39, 173–179 (2012).
  30. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).
  31. Crispin, J. C. & Tsokos, G. C. Human TCR αβ+ CD4– CD8– T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J. Immunol. 183, 4675–4681 (2009).
  32. Shivakumar, S., Tsokos, G. C. & Datta, S. K. T cell receptor α/β expressing double-negative (CD4–/CD8–) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103–112 (1989).
  33. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).
  34. Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).
  35. Furie, R. et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
  36. Eriksson et al., Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden, Arthritis Research & Therapy 2011, 13:R30.
  37. Aho K et al., Antinuclear antibodies heralding the onset of systemic lupus erythematosus., J Rheumatol. 1992 Sep;19(9):1377-9.
  38. Myckatyn et Russell, Outcome of positive antinuclear antibodies in individuals without connective tissue disease, J Rheumatol. 2003 Apr;30(4):736-9.
  39. Arbuckle et al., Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus, N Engl J Med 2003;349:1526-33.
  40. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007;56:2344-2351.
  41. Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014-2021.
  42. Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31:887-892.
  43. Niewold TB, Hua J, Lehman TJ, et al. High serum alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502.
  44. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044-1053.
  45. Lu, R., Munroe, M., Guthridge, J., Bean, K., Fife, D., Chen, H., Slight-Webb, S., Keith, M., Harley, J. and James, J. (2016). Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. Journal of Autoimmunity, 74, pp.182-193.
  46. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in ‘‘healthy’’ individuals. Arthritis Rheum 1997;40:1601e11.
  47. Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, Prigo AM, Rivitti EA. Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo 2003;58: 315e9.
  48. Spiewak R, Stojek N. Antinuclear antibodies among eastern-Polish rural inhabitants. Ann Agric Environ Med 2003;10:207e9.[21] Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G, et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 2005;1050:380e8.
  49. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892e900.
  50. Amy E. Wandstrat и сътр., Autoantibody profiling to identify individuals atrisk for systemic lupus erythematosus, Journal of Autoimmunity 27 (2006) 153-160.
  51. Slight-Webb S. et al, Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity, Arthritis & Rheumatology, Vol. 68, No. 10, October 2016, pp 2492–2502.
  52. Pollak et al, Antinuclear factors in the serum of relatives of patients with systemic lupus erythematosus, Lancet Nov 1960, 1061-103.
  53. Isenberg, D., Shoenfeld, Y., Walport, M., Mackworth-Young, C., Dudeney, C., Todd-Pokropek, A., Brill, S., Weinberger, A. and Pinkas, J. (1985). Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis & Rheumatism, 28(9), pp.999-1007.
  54. Laustrup H et al, Autoantibodies and self-reported health complaints in relatives of systemic lupus erythematosus patients: a community based approach. Lupus. 2004; 13(10):792–9.
  55. Van der Linden MW, Westendorp RG, Zidane M, Meheus L, Huizinga TW. Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens. J Rheumatol. 2001; 28(2):284–7.
  56. Heinlen LD, McClain MT, Kim X, Quintero DR, James JA, Harley JB, Scofield RH. Anti-Ro and anti-nRNP response in unaffected family members of SLE patients. Lupus. 2003; 12(4):335-7.
  57. Reichlin M, Harley JB, Lockshin MD. Serologic studies of monozygotic twins with systemic lupus erythematosus. Arthritis Rheum 1992; 35(4): 457–464.
  58. Laustrup, H., Heegaard, N., Voss, A., Green, A., Lillevang, S. and Junker, P. (2004). Autoantibodies and self-reported health complaints in relatives of systemic lupus erythematosus patients: a community based approach. Lupus, 13(10), pp.792-799.
  59. H Langkilde и сътр., Autoantibodies persist in relatives to systemic lupus еrythematosus patients during 12 years follow-up, Lupus (2016) 0, 1–6.
  60. Munroe МE. et al, Soluble Mediators and Clinical Features Discern Risk of Transitioning to Classified Disease in Relatives of Systemic Lupus Erythematosus Patients, Arthritis Rheumatol. 2017 March ; 69(3): 630–642.
  61. Harel M, Shoenfeld Y., Predicting and preventing autoimmunity, myth or reality?, Ann N Y Acad Sci. 2006 Jun;1069:322-45.
  62. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002; 11(6):356–61.
  63. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401–9.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.